Gilead's Kite To Highlight CAR T-Cell Therapy Portfolio At ASH 2024, Including Survival Outcomes In Both Clinical Trials And The Real-World
Gilead's Kite To Highlight CAR T-Cell Therapy Portfolio At ASH 2024, Including Survival Outcomes In Both Clinical Trials And The Real-World
Kite, a Gilead Company (NASDAQ:GILD), will share 18 presentations, including six oral presentations, demonstrating the strength of its CAR T-cell therapy portfolio across a spectrum of blood cancers during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (December 7-10).– Durability of Response and Continued Manageable Safety Profile for the Phase 1 and iMMagine-1 Studies with Anito-cel in Patients with Relapsed/Refractory Multiple Myeloma to be Presented by Partner Arcellx; Follows Progress with First Patient Dosed in Phase 3 iMMagine-3 Study –
合作伙伴Arcellx将在患有反复/难治性多发性骨髓瘤患者中提出Anito-电芯的第1期和iMMagine-1研究的反应持久性和持续可管理安全性；跟进第3期iMMagine-3研究中首位患者的进展。
– Survival Rate for Yescarta Supported by Largest Real-World Analysis of CAR T for Second-Line Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma –
YESCAR组织的存活率得到了最大规模的实际世界CAR-T细胞治疗作为第二线治疗的支持，针对反复/难治性大B细胞淋巴瘤患者。
– Durability of Response and Long-Term Survival with Yescarta and Tecartus in Multiple Blood Cancers Observed in ZUMA-5, ZUMA-2, and ZUMA-3 Studies –
在ZUMA-5，ZUMA-2和ZUMA-3研究中观察到YESCAR和Tecartus在多种血液癌症中的反应持久性和长期存活。
Kite, a Gilead Company (NASDAQ:GILD), will share 18 presentations, including six oral presentations, demonstrating the strength of its CAR T-cell therapy portfolio across a spectrum of blood cancers during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (December 7-10).
盖利德公司（纳斯达克股票代码：GILD）将分享18个演示文稿，包括六个口头演示，展示其CAR T细胞疗法组合在血液癌症范围内的强大实力，此次展示将在第66届美国血液学会（ASH）年会和博览会（12月7-10日）期间进行。
